Literature DB >> 19095844

Modeling the GABAergic action of etomidate on the thalamocortical system.

Jason A Talavera1, Steven K Esser, Florin Amzica, Sean Hill, Joseph F Antognini.   

Abstract

BACKGROUND: We have used a computational model of the thalamocortical system to investigate the effects of a GABAergic anesthetic (etomidate) on cerebral cortical and thalamic neuronal function. We examined the effects of phasic and tonic inhibition, as well as the relative importance of anesthetic action in the thalamus and cortex.
METHODS: The amount of phasic GABAergic inhibition was adjusted in the model to simulate etomidate concentrations of between 0.25 and 2 microM, with the concentration range producing unconsciousness assumed to be between 0.25 and 0.5 microM. In addition, we modeled tonic inhibition separately, and then phasic and tonic inhibition together. We also introduced phasic and tonic inhibition into the cerebral cortex and thalamus separately to determine the relative importance of each of these structures to anesthetic-induced depression of the thalamocortical system.
RESULTS: Phasic inhibition decreased cortical neuronal firing by 11%-18% in the 0.25-0.5 microM range and by 38% at 2 microM. Tonic inhibition produced similar depression (11%-21%) in the 0.25-0.5 microM range but 65% depression at 2 microM; phasic and tonic inhibition combined produced the most inhibition (76% depression at 2 microM). When the thalamus and cortex were separately subjected to phasic and tonic inhibition, cortical firing rates decreased less compared to when both structures were targeted. In the 0.25-0.5 microM range, cortical firing rate was minimally affected when etomidate action was simulated in the thalamus only.
CONCLUSIONS: This computational model of the thalamocortical system indicated that tonic GABAergic inhibition seems to be more important than phasic GABAergic inhibition (especially at larger etomidate concentrations), although both combined had the most effect on cerebral cortical firing rates. Furthermore, etomidate action in the thalamus, by itself, does not likely explain etomidate-induced unconsciousness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19095844      PMCID: PMC2607049          DOI: 10.1213/ane.0b013e31818d40aa

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  22 in total

Review 1.  General anaesthetic actions on ligand-gated ion channels.

Authors:  M D Krasowski; N L Harrison
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

2.  Neocortex is the major target of sedative concentrations of volatile anaesthetics: strong depression of firing rates and increase of GABAA receptor-mediated inhibition.

Authors:  Harald Hentschke; Cornelius Schwarz; Bernd Antkowiak
Journal:  Eur J Neurosci       Date:  2005-01       Impact factor: 3.386

3.  Modulation of extrasynaptic THIP conductances by GABAA-receptor modulators in mouse neocortex.

Authors:  Kim Ryun Drasbek; Kirsten Hoestgaard-Jensen; Kimmo Jensen
Journal:  J Neurophysiol       Date:  2007-01-10       Impact factor: 2.714

4.  Intracerebral gas anesthesia by diffusion through silicone rubber.

Authors:  J Folkman; V H Mark; F Ervin; K Suematsu; R Hagiwara
Journal:  Anesthesiology       Date:  1968 May-Jun       Impact factor: 7.892

5.  Determination of the EC50 amnesic concentration of etomidate and its diffusion profile in brain tissue: implications for in vitro studies.

Authors:  Claudia Benkwitz; Mark Liao; Michael J Laster; James M Sonner; Edmond I Eger; Robert A Pearce
Journal:  Anesthesiology       Date:  2007-01       Impact factor: 7.892

6.  Distinct functional and pharmacological properties of tonic and quantal inhibitory postsynaptic currents mediated by gamma-aminobutyric acid(A) receptors in hippocampal neurons.

Authors:  D Bai; G Zhu; P Pennefather; M F Jackson; J F MacDonald; B A Orser
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

7.  Biphasic EEG changes in relation to loss of consciousness during induction with thiopental, propofol, etomidate, midazolam or sevoflurane.

Authors:  K Kuizenga; J M Wierda; C J Kalkman
Journal:  Br J Anaesth       Date:  2001-03       Impact factor: 9.166

8.  An extrasynaptic GABAA receptor mediates tonic inhibition in thalamic VB neurons.

Authors:  Fan Jia; Leonardo Pignataro; Claude M Schofield; Minerva Yue; Neil L Harrison; Peter A Goldstein
Journal:  J Neurophysiol       Date:  2005-09-14       Impact factor: 2.714

9.  Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate.

Authors:  Victor Y Cheng; Loren J Martin; Erin M Elliott; John H Kim; Howard T J Mount; Franco A Taverna; John C Roder; John F Macdonald; Amit Bhambri; Neil Collinson; Keith A Wafford; Beverley A Orser
Journal:  J Neurosci       Date:  2006-04-05       Impact factor: 6.167

10.  Extrasynaptic GABAA receptors of thalamocortical neurons: a molecular target for hypnotics.

Authors:  Delia Belelli; Dianne R Peden; Thomas W Rosahl; Keith A Wafford; Jeremy J Lambert
Journal:  J Neurosci       Date:  2005-12-14       Impact factor: 6.167

View more
  4 in total

Review 1.  Dynamical changes in neurological diseases and anesthesia.

Authors:  Michelle M McCarthy; ShiNung Ching; Miles A Whittington; Nancy Kopell
Journal:  Curr Opin Neurobiol       Date:  2012-03-23       Impact factor: 6.627

2.  Sleep and Anesthesia Interactions: A Pharmacological Appraisal.

Authors:  Matthew T Scharf; Max B Kelz
Journal:  Curr Anesthesiol Rep       Date:  2013-03-01

3.  Anesthetic action on extra-synaptic receptors: effects in neural population models of EEG activity.

Authors:  Meysam Hashemi; Axel Hutt; Jamie Sleigh
Journal:  Front Syst Neurosci       Date:  2014-12-10

4.  The general anaesthetic etomidate inhibits the excitability of mouse thalamocortical relay neurons by modulating multiple modes of GABAA receptor-mediated inhibition.

Authors:  Murray B Herd; Jeremy J Lambert; Delia Belelli
Journal:  Eur J Neurosci       Date:  2014-04-29       Impact factor: 3.386

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.